Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Jabbar A, Ingoe L, Thomas H, Carey P, Junejo S, Addison C, Vernazza J, Austin D, Greenwood JP, Zaman A, Razvi S. Prevalence, predictors and outcomes of thyroid dysfunction in patients with acute myocardial infarction: the ThyrAMI-1 study. J Endocrinol Invest 2021;44:1209-1218. [PMID: 32897534 PMCID: PMC8124048 DOI: 10.1007/s40618-020-01408-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Accepted: 08/25/2020] [Indexed: 12/16/2022]

For:	Jabbar A, Ingoe L, Thomas H, Carey P, Junejo S, Addison C, Vernazza J, Austin D, Greenwood JP, Zaman A, Razvi S. Prevalence, predictors and outcomes of thyroid dysfunction in patients with acute myocardial infarction: the ThyrAMI-1 study. J Endocrinol Invest 2021;44:1209-1218. [PMID: 32897534 PMCID: PMC8124048 DOI: 10.1007/s40618-020-01408-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Accepted: 08/25/2020] [Indexed: 12/16/2022]

Number

Cited by Other Article(s)

Zheng Y, Cao Y, Wang W, Tong Y, Wang S, Li C, Zhao M, Song Y, Wang YGS, Qi J, Wu C, Yang J, Zheng J, Gao J, Wang J, Yang Q, Liu G, Zhao J, Zhang Y, Xiao H, Zhang YY, Tang YD. Dusp14-Mediated Dephosphorylation of MLKL Protects Against Cardiomyocyte Necroptosis in Hypothyroidism-Induced Heart Failure. Circulation 2025. [PMID: 40357546 DOI: 10.1161/circulationaha.125.074353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2025] [Accepted: 04/03/2025] [Indexed: 05/15/2025]

Abstract

BACKGROUND

Hypothyroidism leads to multiple organ dysfunction, with the heart the most affected. However, the pathologic mechanism of hypothyroidism-induced heart failure remains to be completely elucidated. Thyroid hormone replacement therapy enhances myocardium systolic function but increases the occurrence of arrythmias. There is an urgent need to explore these mechanisms in detail and to discover and develop drugs that can target and manage heart failure in patients with hypothyroidism.

METHODS

In this study, a mouse model of hypothyroidism-induced heart failure was established through the administration of propylthiouracil. Dusp14 knockout mice were generated, and adeno-associated virus-mediated cardiomyocyte-specific overexpression of Dusp14 (dual specificity phosphatase 14) was used in combination with related cellular experiments to investigate the protective effects of Dusp14 on hypothyroidism-induced heart failure. Further analyses confirmed the crucial involvement of necroptosis in the pathogenesis of hypothyroidism-induced heart failure, and demonstrated the protective role of Dusp14 in modulating necroptosis. In addition, a novel small molecule compound that effectively regulates Dusp14 activity in vitro was identified through molecular docking, providing a potential therapeutic avenue.

RESULTS

Dusp14 regulates necroptosis and mitigates hypothyroidism-induced heart failure. Myocardial tissue sections from mice in the hypothyroidism group showed positive Evans blue dye staining, and the serum levels of the myocardial injury marker lactate dehydrogenase were significantly higher compared with the euthyroid group (n=8). In addition, phosphorylation levels of the necroptosis marker MLKL (mixed lineage kinase domain-like protein) were significantly elevated, indicating the activation of necroptosis (n=8). These findings suggest that myocardial necroptosis is activated during hypothyroidism. Myocardial-specific overexpression of Dusp14 reduced myocardial necroptosis and improved myocardial contractile function in hypothyroid mice (n=8). In contrast, Dusp14 knockout exacerbated myocardial contractile dysfunction and necroptosis in these mice (n=5-7). These results indicate that Dusp14 alleviates hypothyroidism-induced heart failure by inhibiting necroptosis. P077-0472, a small molecule compound, was identified as an activator of Dusp14, which could inhibit cardiomyocyte necroptosis from hypothyroidism (n=6).

CONCLUSIONS

Dusp14 inhibits cardiomyocyte necroptosis from hypothyroidism and consequently rescues damaged cardiomyocytes. P077-0472, a novel small molecule compound that activates the dephosphorylation function of Dusp14, could inhibit cardiomyocyte necroptosis from hypothyroidism.

Collapse

Affiliation(s)

Yitian Zheng Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China (Y. Zheng, W.W., H.X., Y.-Y.Z., Y.-D.T.) Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y. Zheng)
Yueyue Cao Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (Y.C.)
Wenyao Wang Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China (Y. Zheng, W.W., H.X., Y.-Y.Z., Y.-D.T.)
Yicheng Tong Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Shuaixing Wang National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (S.W.)
Chen Li Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Mingming Zhao Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Yao Song Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Yuan-Geng-Shuo Wang Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Jiating Qi Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Chao Wu Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Jie Yang Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Jilin Zheng Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Jun Gao Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Jingjia Wang Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Qing Yang Department of Cardiology, Tianjin Medical University General Hospital, China (Q.Y.)
Gang Liu Department of Cardiology, the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (G.L.)
Jiajun Zhao Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China (J. Zhao)
Yan Zhang Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.)
Han Xiao Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China (Y. Zheng, W.W., H.X., Y.-Y.Z., Y.-D.T.)
You-Yi Zhang Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China (Y. Zheng, W.W., H.X., Y.-Y.Z., Y.-D.T.)
Yi-Da Tang Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.) Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China (Y. Zheng, W.W., H.X., Y.-Y.Z., Y.-D.T.) University of Health and Rehabilitation Sciences, Qingdao, China (Y.-D.T.)

Collapse

Liu L, Cai S, Chen A, Dong Y, Zhou L, Li L, Zhang Z, Hu Z, Zhang Z, Xiong Y, Hu Z, Li Y, Lu M, Wu L, Zheng L, Ding L, Fan X, Yao Y. Long-term prognostic value of thyroid hormones in left ventricular noncompaction. J Endocrinol Invest 2024;47:2185-2200. [PMID: 38358462 PMCID: PMC11369003 DOI: 10.1007/s40618-024-02311-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Accepted: 01/11/2024] [Indexed: 02/16/2024]

Abstract

PURPOSE

Thyroid function is closely related to the prognosis of cardiovascular diseases. This study aimed to explore the predictive value of thyroid hormones for adverse cardiovascular outcomes in left ventricular noncompaction (LVNC).

METHODS

This longitudinal cohort study enrolled 388 consecutive LVNC patients with complete thyroid function profiles and comprehensive cardiovascular assessment. Potential predictors for adverse outcomes were thoroughly evaluated.

RESULTS

Over a median follow-up of 5.22 years, primary outcome (the combination of cardiovascular mortality and heart transplantation) occurred in 98 (25.3%) patients. For secondary outcomes, 75 (19.3%) patients died and 130 (33.5%) patients experienced major adverse cardiovascular events (MACE). Multivariable Cox analysis identified that free triiodothyronine (FT3) was independently associated with both primary (HR 0.455, 95%CI 0.313-0.664) and secondary (HR 0.547, 95%CI 0.349-0.858; HR 0.663, 95%CI 0.475-0.925) outcomes. Restricted cubic spline analysis illustrated that the risk for adverse outcomes increased significantly with the decline of serum FT3. The LVNC cohort was further stratified according to tertiles of FT3 levels. Individuals with lower FT3 levels in the tertile 1 group suffered from severe cardiac dysfunction and remodeling, resulting in higher incidence of mortality and MACE (Log-rank P < 0.001). Subgroup analysis revealed that lower concentration of FT3 was linked to worse prognosis, particularly for patients with left atrial diameter ≥ 40 mm or left ventricular ejection fraction ≤ 35%. Adding FT3 to the pre-existing risk score for MACE in LVNC improved its predictive performance.

CONCLUSION

Through the long-term investigation on a large LVNC cohort, we demonstrated that low FT3 level was an independent predictor for adverse cardiovascular outcomes.

Collapse

Affiliation(s)

L Liu Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
S Cai Cardiac Arrhythmia Center, Heart Center, The People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Huazhong Fuwai Hospital, Zhengzhou, Henan, China
A Chen Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
Y Dong Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
L Zhou Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
L Li Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
Z Zhang Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
Z Hu Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
Z Zhang Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
Y Xiong Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
Z Hu Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
Y Li Department of Echocardiography, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
M Lu Department of Magnetic Resonance Imaging, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
L Wu Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
L Zheng Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
L Ding Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
X Fan Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China
Y Yao Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China.

Collapse

Shen X, Wu S, Yan J, Yan H, Zhou S, Weng H, Yang S, Li W. Prognostic implications of thyroid hormones in acute aortic dissection: mediating roles of renal function and coagulation. Front Endocrinol (Lausanne) 2024;15:1387845. [PMID: 39157680 PMCID: PMC11327079 DOI: 10.3389/fendo.2024.1387845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2024] [Accepted: 07/17/2024] [Indexed: 08/20/2024] Open

Affiliation(s)

Xuejun Shen Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Shantou University Medical College, Shantou, Guangdong, China
Shiwan Wu Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
Jingyi Yan Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Shantou University Medical College, Shantou, Guangdong, China
Hongle Yan Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Shantou University Medical College, Shantou, Guangdong, China
Shuyi Zhou Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Shantou University Medical College, Shantou, Guangdong, China
Huozhen Weng Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Shantou University Medical College, Shantou, Guangdong, China
Shengli Yang Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
Weiping Li Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China

Collapse

Liu L, Zeng B, Zhang J, Li G, Zong W. Impact of subclinical hypothyroidism on in-hospital outcomes and long-term mortality among acute myocardial infarction patients with diabetic mellitus. Acta Cardiol 2024;79:650-658. [PMID: 37961871 DOI: 10.1080/00015385.2023.2279421] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 10/01/2023] [Accepted: 10/31/2023] [Indexed: 11/15/2023]

Patrizio A, Ferrari SM, Elia G, Ragusa F, Balestri E, Botrini C, Rugani L, Mazzi V, Antonelli A, Fallahi P, Benvenga S. Hypothyroidism and metabolic cardiovascular disease. Front Endocrinol (Lausanne) 2024;15:1408684. [PMID: 38887272 PMCID: PMC11180764 DOI: 10.3389/fendo.2024.1408684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Accepted: 05/20/2024] [Indexed: 06/20/2024] Open

Kumar R, Sinha R, Gunjan G, Singh SK. A Cross-Sectional Study of Acute Coronary Syndrome and Thyroid Profile: Dissecting the Relationship to Improve Patient Care. Cureus 2024;16:e55793. [PMID: 38586744 PMCID: PMC10999166 DOI: 10.7759/cureus.55793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2024] [Indexed: 04/09/2024] Open

Abstract

INTRODUCTION

Thyroid-releasing hormones are pivotal in regulating cardiovascular (CVS) function and maintaining its hemodynamics and homeostasis. Even a minor alteration in thyroid function has an enormous implication on CVS morbidity and mortality. Moreover, hypothyroidism was found to be a potential menace for coronary artery disease (CAD). The objective of this study was to determine the role of thyroid-releasing hormones in patients suffering from acute coronary syndrome (ACS).

METHODOLOGY

Among a cohort of 100 patients suffering with ACS, a complete history and clinical information followed by physical examination and electrocardiography were recorded. Blood samples were also collected to record the blood sugar levels i.e., fasting blood sugar (FBS), postprandial blood sugar (PPBS), and thyroid profile, including free thyroid stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3), and reverse triiodothyronine (rT3). The data was analyzed using SPSS version 26 software (IBM Corp., Armonk, NY, USA).

RESULT

The study identified alterations in the thyroid hormone levels in 27% of patients suffering from ACS. The prevalence of euthyroid sick syndrome was found to be 59.3%, while subclinical hypothyroidism and subclinical hyperthyroidism were reported among 18.5% and 14.8% of patients respectively. There was no significant difference found between males and females. The study illustrated a greater occurrence of aberrant thyroid hormone profiles among those aged 40-60 years. The ST-elevated myocardial infarction (STEMI) group had a statistically significant higher prevalence of an aberrant thyroid hormone profile compared to the non-ST-elevated myocardial infarction (NSTEMI) and unstable angina (UA) groups (p=0.02). A total of nine patients died with ACS and all of those had statistically significant low fT3 and TSH values while higher rT3 values (p<0.05).

CONCLUSION

An atypical thyroid status has been found to elevate the likelihood of developing CAD and experiencing CVS mortality. This condition can impact ventricular function and serum cholesterol levels as well as heart rate and rhythm. Therefore, understanding this relationship could potentially lead to improved treatment strategies for individuals with ACS which will further prevent major CVS complications.

Collapse

Mantzouratou P, Malaxianaki E, Cerullo D, Lavecchia AM, Pantos C, Xinaris C, Mourouzis I. Thyroid Hormone and Heart Failure: Charting Known Pathways for Cardiac Repair/Regeneration. Biomedicines 2023;11:975. [PMID: 36979954 PMCID: PMC10046827 DOI: 10.3390/biomedicines11030975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 03/17/2023] [Accepted: 03/20/2023] [Indexed: 03/30/2023] Open

Pantos CI, Trikas AG, Pissimisis EG, Grigoriou KP, Stougiannos PN, Dimopoulos AK, Linardakis SI, Alexopoulos NA, Evdoridis CG, Gavrielatos GD, Patsourakos NG, Papakonstantinou ND, Theodosis-Georgilas AD, Mourouzis IS. Effects of Acute Triiodothyronine Treatment in Patients with Anterior Myocardial Infarction Undergoing Primary Angioplasty: Evidence from a Pilot Randomized Clinical Trial (ThyRepair Study). Thyroid 2022;32:714-724. [PMID: 35297659 DOI: 10.1089/thy.2021.0596] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]

Abstract

Background: Thyroid hormone has a differential action on healthy and ischemic heart. Triiodothyronine (T3) administration improved postischemic cardiac function while it limited apoptosis in experimentally induced ischemia. Thus, the present study investigated the potential effects of acute liothyronine (LT3) treatment in patients with anterior myocardial infarction. Methods: This study is a pilot, randomized, double-blind, placebo-controlled trial (ThyRepair study). We randomized 52 patients and analyzed data from 37 patients (n = 16 placebo and n = 21 LT3), per prespecified per protocol analysis. We excluded three patients who had died of cardiovascular causes (one in placebo and two in LT3 arm), four with small infarct size below a pre-specified threshold (in the placebo arm), and the rest, who lacked follow-up data. LT3 treatment started after stenting as an intravenous (i.v.) bolus injection of 0.8 μg/kg of LT3 followed by a constant infusion of 0.113 μg/kg/h i.v. for 48 hours. All patients had cardiac magnetic resonance (CMR) at hospital discharge and 6 months follow-up. The primary end point was CMR left ventricular (LV) ejection fraction (LVEF) and secondary endpoints were LV volumes, infarct volume (IV), and safety. Results: The CMR LVEF% at 6 months was 53.6 ± 9.5 for the LT3-treated group and 48.6 ± 11 for placebo, p = 0.15. Acute LT3 treatment resulted in a significantly lower LV end-diastolic volume index (92.2 ± 16.8 mL/m² vs. 107.5 ± 22.2, p = 0.022) and LV systolic volume index (47.5 ± 13.9 mL/m² vs. 61.3 ± 21.7, p = 0.024) at hospital discharge, but not at 6 months. There was no statistically significant difference in CMR IV at hospital discharge between the groups (p = 0.24). CMR IV tended to be lower in the LT3-treated group at 6 months (18.7 ± 9.5 vs. 25.9 ± 11.7, in placebo, p = 0.05). Serious, life-threatening events related to LT3 treatment were not observed. A tendency for an increased incidence of atrial fibrillation (AF) was found in the LT3 group during the first 48 hours (19% for T3 group vs. 5% for placebo, p = 0.13). Conclusion: This pilot randomized, placebo-controlled trial study suggests potential favorable effects (acute cardiac dilatation and 6-month IV) as well as potential concerns regarding a higher risk of AF after LT3 administration early after myocardial infarction, which should be tested in a larger scale study.

Collapse

Endurance Training and Consumption of Hydroalcoholic Zingiber Officinale Extract Regulated PPARγ, PGC1-ɑ/TNF-ɑ Expression Level in Myocardial Infarction Rats. JORJANI BIOMEDICINE JOURNAL 2022. [DOI: 10.52547/jorjanibiomedj.10.2.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]

Yang J, Zheng Y, Li C, Liu Y, Zhou Q, Gao J, Meng X, Zhang K, Wang W, Shao C, Tang YD. The Impact of Subclinical Hyperthyroidism on Cardiovascular Prognosis in Patients Undergoing Percutaneous Coronary Intervention. J Clin Endocrinol Metab 2022;107:986-997. [PMID: 34850030 DOI: 10.1210/clinem/dgab855] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Indexed: 01/15/2023]

Affiliation(s)

Jie Yang Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Yitian Zheng Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Chen Li Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Yupeng Liu Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Qing Zhou Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Jun Gao Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China
Xiangbin Meng Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China
Kuo Zhang Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Wenyao Wang Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Chunli Shao Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China
Yi-Da Tang Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China

Collapse

Paschou SA, Bletsa E, Stampouloglou PK, Tsigkou V, Valatsou A, Stefanaki K, Kazakou P, Spartalis M, Spartalis E, Oikonomou E, Siasos G. Thyroid disorders and cardiovascular manifestations: an update. Endocrine 2022;75:672-683. [PMID: 35032315 DOI: 10.1007/s12020-022-02982-4] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Accepted: 01/09/2022] [Indexed: 12/25/2022]

Affiliation(s)

Stavroula A Paschou Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Evanthia Bletsa 3rd Department of Cardiology, Sotiria Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Panagiota K Stampouloglou 3rd Department of Cardiology, Sotiria Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Vasiliki Tsigkou 3rd Department of Cardiology, Sotiria Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Angeliki Valatsou 1st Department of Cardiology, Hippokration General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Katerina Stefanaki Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Paraskevi Kazakou Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Michael Spartalis 3rd Department of Cardiology, Sotiria Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Eleftherios Spartalis 2nd Department of Propaedeutic Surgery, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Evangelos Oikonomou 3rd Department of Cardiology, Sotiria Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Gerasimos Siasos 3rd Department of Cardiology, Sotiria Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Collapse

Li MF, Wei ZT, Li S, Feng QM, Li JB. Association of Mild Thyroid Dysfunction and Adverse Prognosis Among Chinese Patients With Acute ST Segment Elevation Myocardial Infarction. Front Endocrinol (Lausanne) 2022;13:879443. [PMID: 35574034 PMCID: PMC9097552 DOI: 10.3389/fendo.2022.879443] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2022] [Accepted: 03/28/2022] [Indexed: 11/13/2022] Open

Pingitore A, Mastorci F, Berti S, Sabatino L, Palmieri C, Iervasi G, Vassalle C. Hypovitaminosis D and Low T3 Syndrome: A Link for Therapeutic Challenges in Patients with Acute Myocardial Infarction. J Clin Med 2021;10:jcm10225267. [PMID: 34830551 PMCID: PMC8625651 DOI: 10.3390/jcm10225267] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 10/29/2021] [Accepted: 11/09/2021] [Indexed: 11/24/2022] Open

Zhu Y, Shen J, Xue Y, Xiang Z, Jiang Y, Zhou W, Luo S. The Association between Thyroid-Stimulating Hormone and Long-Term Outcomes in Patients with ST Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. Int J Gen Med 2021;14:6295-6303. [PMID: 34629894 PMCID: PMC8494999 DOI: 10.2147/ijgm.s333322] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 09/23/2021] [Indexed: 12/11/2022] Open